Lexeo Therapeutics, Inc.
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy (ACM), and others in devastating diseases with high unmet need.
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
LX2006 in Friedreich ataxia
CEO
R. Nolan Townsend
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
We have three clinical-stage gene therapy assets for APOE4-associated Alzheimer’s disease, for which we are seeking development partners.
Exchange
Nasdaq
Ticker
LXEO
When you expect your next catalyst update?
Please see above.
What is your next catalyst (value inflection) update?
We expect to initiate the SUNRISE-FA 2 registrational study of LX2006 in the first half of 2026, with a potential topline efficacy readout in 2027. Beyond our lead program, we expect to share interim Phase I/II clinical data from the LX2020 program in PKP2-ACM in Q4 2026.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}